CYP17A1/HDAC6-IN-1

CYP17A1/HDAC6-IN-1 (compound 12) is a potent inhibitor of CYP17A1/HDAC6, with IC50 of 0.284μM and 0.6015 μM, respectively. CYP17A1/HDAC6-IN-1 has anti-tumor activity[1].

Product Specifications

CAS Number

[3047489-22-2]

UNSPSC

12352005

Target

Cytochrome P450; HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cyp17a1-hdac6-in-1.html

Solubility

10 mM in DMSO

Smiles

C[C@@]12[C@](CC=C2C3=CN=CC=C3)([H])[C@@]4([H])[C@@](CC1)([H])[C@@]5(C(C[C@H](CC5)OC(CCCCCC(NO)=O)=O)=CC4)C

Molecular Formula

C31H42N2O4

Molecular Weight

506.68

References & Citations

[1]Ram Sharma, et al. Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress. Cancer Lett. 2024 Feb 2:586:216666.